Form 13-F position report

CYMABAY THERAPEUTICS INC

Reported by Boxer Capital LLC

CBAY CUSIP 23257D103 Manager CIK 0001465837

Reported 4,000,000 shares, up 2,000,000 (100.0%) from the prior quarter.

Reported value 314.9%; share count 100.0% vs. the prior quarter.

Added
% of reported 13F value 1.0% This manager · Q3 2020
Shares 4,000,000 Quarter-end amount reported
Reported value $28,960,000 Fair value at quarter end
Consecutive quarters held 15 Through Q3 2020

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2020-03-31 2960000
2020-06-30 6980000
2020-09-30 28960000
2020-12-31 22960000
2021-03-31 18160000
2021-06-30 17440000
2021-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

7 quarters
Quarterly reported position history for CYMABAY THERAPEUTICS INC held by Boxer Capital LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2021 Reduced 0 -4,000,000 (-100.0%) 0 $0 2021-11-15
Q2 2021 Unchanged 4,000,000 0 (0.0%) 0.62% $17,440,000 2021-08-16
Q1 2021 Unchanged 4,000,000 0 (0.0%) 0.62% $18,160,000 2021-05-17
Q4 2020 Unchanged 4,000,000 0 (0.0%) 0.74% $22,960,000 2021-02-16
Q3 2020 Added 4,000,000 +2,000,000 (100.0%) 1.0% $28,960,000 2020-11-16
Q2 2020 Unchanged 2,000,000 0 (0.0%) 0.31% $6,980,000 2020-08-14
Q1 2020 Unchanged 2,000,000 0 (0.0%) 0.2% $2,960,000 2020-05-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

135 managers reported CYMABAY THERAPEUTICS INC for Q3 2020.

Managers reporting CYMABAY THERAPEUTICS INC in Q3 2020.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Avoro Capital Advisors LLC Added 10,300,000 +5,050,000 1.06% $74,572,000 7 qtrs
BlackRock Inc Reduced 5,130,908 -485,654 < 0.01% $37,147,000 15 qtrs
Boxer Capital LLC This report Added 4,000,000 +2,000,000 1.0% $28,960,000 15 qtrs
VANGUARD GROUP INC Reduced 3,373,119 -7,256 < 0.01% $24,422,000 25 qtrs
BAKER BROS ADVISORS LP Added 3,252,542 +1,729,750 0.09% $23,548,000 2 qtrs
CITADEL ADVISORS LLC Reduced 2,221,555 -478,543 < 0.01% $16,084,000 19 qtrs
Vivo Capital LLC Unchanged 2,089,356 0 0.87% $15,127,000 3 qtrs
Invesco Ltd Added 1,877,586 +1,781,858 < 0.01% $13,594,000 6 qtrs
Foresite Capital Management IV LLC Reduced 1,787,094 -1,056,799 2.92% $12,939,000 12 qtrs
Redmile Group LLC Added 1,719,247 +44,800 0.23% $12,447,000 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2020
Filed
November 16, 2020
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
4,000,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.